IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3679
-0.0178 (-4.61%)
Nov 7, 2025, 4:00 PM EST - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $328.00K in the quarter ending June 30, 2025, with 20.59% growth. This brings the company's revenue in the last twelve months to $1.33M, up 24.95% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.33M
Revenue Growth
+24.95%
P/S Ratio
21.92
Revenue / Employee
$18,957
Employees
70
Market Cap
33.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IGC News
- 5 days ago - IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline - Accesswire
- 17 days ago - IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" - Accesswire
- 25 days ago - IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences - Accesswire
- 4 weeks ago - IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders - Accesswire
- 4 weeks ago - IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease - Accesswire
- 5 weeks ago - IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial - Accesswire
- 6 weeks ago - IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology - Accesswire
- 6 weeks ago - IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - Accesswire